Compare GKOS & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | G |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.2B |
| IPO Year | 2015 | N/A |
| Metric | GKOS | G |
|---|---|---|
| Price | $116.17 | $38.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $133.07 | $49.50 |
| AVG Volume (30 Days) | 770.3K | ★ 2.6M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.91% |
| EPS Growth | ★ 0.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $383,481,000.00 | N/A |
| Revenue This Year | $23.29 | $8.88 |
| Revenue Next Year | $27.74 | $7.47 |
| P/E Ratio | ★ N/A | $12.52 |
| Revenue Growth | ★ 21.85 | N/A |
| 52 Week Low | $73.16 | $34.79 |
| 52 Week High | $142.50 | $55.00 |
| Indicator | GKOS | G |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 38.85 |
| Support Level | $103.55 | $36.50 |
| Resistance Level | $121.70 | $41.00 |
| Average True Range (ATR) | 5.70 | 1.86 |
| MACD | -0.23 | -0.08 |
| Stochastic Oscillator | 63.83 | 39.23 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.